b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">30548896</PMID>\n        <DateCompleted>\n            <Year>2020</Year>\n            <Month>04</Month>\n            <Day>03</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>04</Month>\n            <Day>03</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1399-0012</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>33</Volume>\n                    <Issue>2</Issue>\n                    <PubDate>\n                        <Year>2019</Year>\n                        <Month>02</Month>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Clinical transplantation</Title>\n                <ISOAbbreviation>Clin Transplant</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Optimizing the clinical utility of sirolimus-based immunosuppression for kidney transplantation.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>e13464</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1111/ctr.13464</ELocationID>\n            <Abstract>\n                <AbstractText>While calcineurin inhibitors (CNIs) are effective for preventing acute rejection in kidney transplant recipients, long-term use may cause chronic kidney injury and is associated with increased risks of cardiovascular events, cancer, and infection-associated death. Immunosuppression strategies are needed to balance risks of acute and subclinical rejection with long-term benefits of improved kidney function. Sirolimus, an inhibitor of mammalian target of rapamycin, is used for immunosuppression in kidney transplantation. Its clinical utility has evolved, over more than 15\xc2\xa0years, including de novo sirolimus with and without concomitant CNIs and conversion from CNI-based regimens to sirolimus. Sirolimus-containing regimens are associated with preservation of good renal function, with promising characteristics for improving long-term graft and patient survival, including antiviral and anticancer effects. Based on clinical evidence, use of low-dose sirolimus in a de novo approach with tacrolimus/steroids in the immediate posttransplantation period is appropriate. A feasible alternative is a long term, CNI-free combination with mycophenolate mofetil (following CNI-to-sirolimus conversion at 3-6\xc2\xa0months). These strategies are appropriate for a broad range of patients with various levels of immunologic risk, including those receiving expanded criteria donor kidneys or at increased risk of delayed graft function, particular challenges in Latin America and other global regions.</AbstractText>\n                <CopyrightInformation>\xc2\xa9 2018 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Tedesco-Silva</LastName>\n                    <ForeName>Helio</ForeName>\n                    <Initials>H</Initials>\n                    <Identifier Source="ORCID">0000-0002-9896-323X</Identifier>\n                    <AffiliationInfo>\n                        <Affiliation>Divis\xc3\xa3o de Nefrologia, Hospital do Rim, Universidade Federal de S\xc3\xa3o Paulo, S\xc3\xa3o Paulo, Brazil.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Del Carmen Rial</LastName>\n                    <ForeName>Maria</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Instituto de Nefrologia, Nephrology SA, Institucion afiliada a Universidad de Buenos Aires, Buenos Aires, Argentina.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Cruz Santiago</LastName>\n                    <ForeName>Jose</ForeName>\n                    <Initials>J</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Hospital de Especialidades CMN La Raza IMSS Mexico, Mexico City, Mexico.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Mazzali</LastName>\n                    <ForeName>Marilda</ForeName>\n                    <Initials>M</Initials>\n                    <Identifier Source="ORCID">0000-0001-6297-4909</Identifier>\n                    <AffiliationInfo>\n                        <Affiliation>University of Campinas, S\xc3\xa3o Paulo, Brazil.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Pacheco-Silva</LastName>\n                    <ForeName>Alvaro</ForeName>\n                    <Initials>A</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Divis\xc3\xa3o de Nefrologia, Hospital do Rim, Universidade Federal de S\xc3\xa3o Paulo, S\xc3\xa3o Paulo, Brazil.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Hospital Israelita Albert Einstein, S\xc3\xa3o Paulo, Brazil.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Torres</LastName>\n                    <ForeName>Rodolfo</ForeName>\n                    <Initials>R</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Cl\xc3\xadnica Universitaria Colombia, Fundacion Universit\xc3\xa1ria de Ciencias de la Salud, Bogot\xc3\xa1, Colombia.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n                <PublicationType UI="D013485">Research Support, Non-U.S. Gov\'t</PublicationType>\n                <PublicationType UI="D016454">Review</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2019</Year>\n                <Month>01</Month>\n                <Day>02</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>Denmark</Country>\n            <MedlineTA>Clin Transplant</MedlineTA>\n            <NlmUniqueID>8710240</NlmUniqueID>\n            <ISSNLinking>0902-0063</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>W36ZG6FT64</RegistryNumber>\n                <NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D006084" MajorTopicYN="N">Graft Rejection</DescriptorName>\n                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>\n                <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006085" MajorTopicYN="N">Graft Survival</DescriptorName>\n                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D007676" MajorTopicYN="N">Kidney Failure, Chronic</DescriptorName>\n                <QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D016030" MajorTopicYN="N">Kidney Transplantation</DescriptorName>\n                <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D020123" MajorTopicYN="N">Sirolimus</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>\n            </MeshHeading>\n        </MeshHeadingList>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="Y">Rapamune</Keyword>\n            <Keyword MajorTopicYN="Y">calcineurin inhibitors</Keyword>\n            <Keyword MajorTopicYN="Y">complementary therapies</Keyword>\n            <Keyword MajorTopicYN="Y">immunosuppressive agents</Keyword>\n            <Keyword MajorTopicYN="Y">renal transplantation</Keyword>\n            <Keyword MajorTopicYN="Y">sirolimus/administration &amp; dosage</Keyword>\n            <Keyword MajorTopicYN="Y">transplant recipients</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2017</Year>\n                <Month>10</Month>\n                <Day>26</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="revised">\n                <Year>2018</Year>\n                <Month>11</Month>\n                <Day>06</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2018</Year>\n                <Month>12</Month>\n                <Day>06</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2018</Year>\n                <Month>12</Month>\n                <Day>15</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2020</Year>\n                <Month>4</Month>\n                <Day>4</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2018</Year>\n                <Month>12</Month>\n                <Day>15</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">30548896</ArticleId>\n            <ArticleId IdType="doi">10.1111/ctr.13464</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'